UA107200C2 - ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα - Google Patents

ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα

Info

Publication number
UA107200C2
UA107200C2 UAA201204796A UAA201204796A UA107200C2 UA 107200 C2 UA107200 C2 UA 107200C2 UA A201204796 A UAA201204796 A UA A201204796A UA A201204796 A UAA201204796 A UA A201204796A UA 107200 C2 UA107200 C2 UA 107200C2
Authority
UA
Ukraine
Prior art keywords
single variable
tnfb
receptor
immunoglobulin domain
domain against
Prior art date
Application number
UAA201204796A
Other languages
English (en)
Russian (ru)
Inventor
Сілва Інуша де
Армін Сепп
Едріан Алларт Ступ
Original Assignee
Ґлаксо Ґруп Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107200(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ґлаксо Ґруп Лімітед filed Critical Ґлаксо Ґруп Лімітед
Publication of UA107200C2 publication Critical patent/UA107200C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Винахід стосується стійкого при зберіганні одиничного варіабельного домену імуноглобуліну проти рецептора типу 1 TNFα (TNFR1; р55), що включає амінокислотну послідовність, яка є ідентичною амінокислотній послідовності DOM1h-574-208 (SEQ ID NO: 59), антагоніста, що його включає, та мультиспецифічного ліганду, а також їх застосування для лікування та/або попередження запального захворювання, зокрема артриту.
UAA201204796A 2009-10-27 2010-10-25 ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα UA107200C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25523509P 2009-10-27 2009-10-27
PCT/EP2010/066046 WO2011051217A1 (en) 2009-10-27 2010-10-25 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Publications (1)

Publication Number Publication Date
UA107200C2 true UA107200C2 (uk) 2014-12-10

Family

ID=43382391

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204796A UA107200C2 (uk) 2009-10-27 2010-10-25 ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα

Country Status (26)

Country Link
US (1) US20150210767A1 (uk)
EP (1) EP2493504B1 (uk)
JP (1) JP2013507978A (uk)
KR (1) KR20120101417A (uk)
CN (1) CN102686239B (uk)
AR (1) AR078763A1 (uk)
AU (1) AU2010311640B2 (uk)
BR (1) BR112012010114A2 (uk)
CA (1) CA2777312A1 (uk)
CL (1) CL2012001055A1 (uk)
CO (1) CO6612254A2 (uk)
CR (1) CR20120197A (uk)
DO (1) DOP2012000113A (uk)
EA (1) EA022898B1 (uk)
ES (1) ES2552177T3 (uk)
IL (1) IL218860A0 (uk)
MA (1) MA33758B1 (uk)
MX (1) MX2012005024A (uk)
NZ (1) NZ599114A (uk)
PE (1) PE20121564A1 (uk)
SG (1) SG10201500274TA (uk)
TW (1) TW201125877A (uk)
UA (1) UA107200C2 (uk)
UY (1) UY32969A (uk)
WO (1) WO2011051217A1 (uk)
ZA (1) ZA201203052B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
EP2721066A1 (en) * 2011-06-17 2014-04-23 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
SG11201505388QA (en) * 2013-01-31 2015-08-28 Glaxo Group Ltd Method of producing a protein
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
CN109641958B (zh) * 2016-04-05 2023-10-31 斯图加特大学 huTNFR1相互作用的单价抑制剂
KR20230078657A (ko) 2020-08-27 2023-06-02 에노시 테라퓨틱스 코퍼레이션 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN114699533B (zh) * 2022-05-06 2023-05-09 郑州大学 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
EP1801214B1 (en) 1997-07-07 2010-11-10 Medical Research Council In vitro sorting method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1627062A1 (en) 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
NZ548612A (en) 2004-02-09 2009-11-27 Human Genome Sciences Inc Albumin fusion proteins comprising tandem GLP-1
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
SG173489A1 (en) * 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants

Also Published As

Publication number Publication date
WO2011051217A1 (en) 2011-05-05
TW201125877A (en) 2011-08-01
CL2012001055A1 (es) 2012-10-05
CA2777312A1 (en) 2011-05-05
UY32969A (es) 2011-05-31
IL218860A0 (en) 2012-06-28
DOP2012000113A (es) 2012-08-15
NZ599114A (en) 2014-09-26
KR20120101417A (ko) 2012-09-13
MA33758B1 (fr) 2012-11-01
AU2010311640A1 (en) 2012-05-10
EA201290172A1 (ru) 2013-04-30
SG10201500274TA (en) 2015-03-30
AR078763A1 (es) 2011-11-30
CR20120197A (es) 2012-06-22
CN102686239A (zh) 2012-09-19
US20150210767A1 (en) 2015-07-30
ZA201203052B (en) 2013-09-25
CN102686239B (zh) 2016-02-03
EP2493504A1 (en) 2012-09-05
EP2493504B1 (en) 2015-10-07
JP2013507978A (ja) 2013-03-07
BR112012010114A2 (pt) 2017-08-08
EA022898B1 (ru) 2016-03-31
ES2552177T3 (es) 2015-11-26
MX2012005024A (es) 2012-09-07
AU2010311640B2 (en) 2015-01-29
CO6612254A2 (es) 2013-02-01
PE20121564A1 (es) 2012-11-29

Similar Documents

Publication Publication Date Title
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
UA107200C2 (uk) ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα
MX2009012967A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
MX2009012968A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
WO2008149146A3 (en) Polypeptides, antibody variable domains and antagonists
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
WO2009074634A3 (en) Polypeptides, antibody variable domains & antagonists
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
UA109888C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
MX2012015260A (es) Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4.
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
WO2012054526A8 (en) Chemosensory receptor ligand-based therapies
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
JO2645B1 (en) Vehicles
WO2011088385A3 (en) Compositions and methods for detecting cancer
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
WO2012054530A3 (en) Chemosensory receptor ligand-based therapies
NO20090539L (no) Azaindolderivater med en kombinasjon av partiell nikotinacetylcholinreseptoragonisme og dopamin gjenopptakelsesinhibisjon
WO2012019192A3 (en) Cell-permeable molecules as growth factor receptor antagonists